Regenear Overview

  • Founded
  • 2010
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $2.21M
Latest Deal Amount
  • Investors
  • 1

Regenear General Information


Provider of biomedical services. The Company specializes in developing and commercializing he first biokits to regenerate tridimensional facial cartilage from patient's own cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • Carrer Joan Blanques 26-28
  • 08012 Barcelona
  • Spain
+34 932 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Regenear Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 22-Apr-2014 $2.21M 00.000 Completed Startup
To view Regenear’s complete valuation and funding history, request access »

Regenear Executive Team (4)

Name Title Board Seat Contact Info
Àgata Gelabertó Co-Founder & Chief Executive Officer
Albert Milé Co-Founder & Financial Vice President
Elazer Edelman MD Co-Founder
Mercedes Balcells Ph.D Co-Founder & Vice President, Research & Development
To view Regenear’s complete executive team members history, request access »

Regenear Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Regenear Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Building Global Innovators Accelerator/Incubator 000 0000 000000 0
To view Regenear’s complete investors history, request access »